NCT07264270 Study to Evaluate Safety of C-1101 Versus Sterile Saline in Adults With Chronic Painful Lumbosacral Radiculopathy
| NCT ID | NCT07264270 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Consano Bio |
| Condition | Lumbosacral Radicular Pain |
| Study Type | INTERVENTIONAL |
| Enrollment | 24 participants |
| Start Date | 2025-12-03 |
| Primary Completion | 2027-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 24 participants in total. It began in 2025-12-03 with a primary completion date of 2027-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate the safety and tolerability of C-1101 administered as a single dose, transforaminal epidural injection compared to sterile saline
Eligibility Criteria
Inclusion Criteria: * Diagnosis of painful LSR (sciatica) radiating to or below the knee, with an inadequate response to conservative care * Body mass index \< 40 kg/m2. Exclusion Criteria: * Presence of clinically significant disease or any other painful condition that may interfere with assessments. * Any condition that currently requires blood or platelet transfusions. * Diagnosed with schizophrenia, bipolar disorder, or major depressive disorder. * Increased risk of bleeding or is taking anticoagulants or platelet aggregation inhibitors. * History or presence of autonomic neuropathy, diabetic neuropathy, or other peripheral neuropathies. * History of myocardial infarction within the last 6 months or congestive heart failure. * The presence of an active malignancy or tumor. * Have undergone a surgical procedure for back pain. * Recent use of immunosuppressants, oral steroids, or intravenous steroids.
Contact & Investigator
Senior Director, Clinical Development Operations
✉ ClinicalDev@consanobio.com📞 U.S.:+1-508-492-0599
Consano Chief Medical Officer
STUDY DIRECTOR
Consano Bio
Frequently Asked Questions
Who can join the NCT07264270 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Lumbosacral Radicular Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07264270 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07264270 currently recruiting?
Yes, NCT07264270 is actively recruiting participants. Contact the research team at ClinicalDev@consanobio.com for enrollment information.
Where is the NCT07264270 trial being conducted?
This trial is being conducted at Fernandina Beach, United States, Winston-Salem, United States, Richmond, United States, Broadmeadow, Australia and 2 additional locations.
Who is sponsoring the NCT07264270 clinical trial?
NCT07264270 is sponsored by Consano Bio. The principal investigator is Consano Chief Medical Officer at Consano Bio. The trial plans to enroll 24 participants.